BiotechTube

KRN23

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome

Conditions

Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome

Trial Timeline

Apr 1, 2016 → Oct 1, 2020

NCT ID
NCT02722798

About KRN23

KRN23 is a phase 2 stage product being developed by Kyowa Kirin for Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02722798. Target conditions include Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (10)

NCT IDPhaseStatus
NCT05357573ApprovedCompleted
NCT04842032ApprovedCompleted
NCT04842019ApprovedCompleted
NCT04308096Phase 3Completed
NCT03233126Phase 3Completed
NCT02722798Phase 2Completed
NCT02312687Phase 2Completed
NCT02181764Phase 1Completed
NCT01571596Phase 1/2Completed
NCT01340482Phase 1/2Completed

Competing Products

1 competing product in Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome

See all competitors
ProductCompanyStageHype Score
KRN23Kyowa KirinApproved
85

Other Products from Kyowa Kirin

KRN23Approved
85
Istradefylline PillApproved
85
MogamulizumabApproved
85
KRN23Approved
85
KHK4827-Active + KHK4827-PlaceboApproved
85